BR112014014289A2 - método de tratamento de diabetes, formulação para administração oral, composição, e, uso de qualquer um ou mais dos compostos fenoxipirimidinona e insulina - Google Patents
método de tratamento de diabetes, formulação para administração oral, composição, e, uso de qualquer um ou mais dos compostos fenoxipirimidinona e insulinaInfo
- Publication number
- BR112014014289A2 BR112014014289A2 BR112014014289A BR112014014289A BR112014014289A2 BR 112014014289 A2 BR112014014289 A2 BR 112014014289A2 BR 112014014289 A BR112014014289 A BR 112014014289A BR 112014014289 A BR112014014289 A BR 112014014289A BR 112014014289 A2 BR112014014289 A2 BR 112014014289A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenoxypyrimidinone
- formulation
- composition
- oral administration
- treatment method
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- VPIGRDOQICYMAJ-UHFFFAOYSA-N 6-phenoxy-1h-pyrimidin-2-one Chemical compound OC1=NC=CC(OC=2C=CC=CC=2)=N1 VPIGRDOQICYMAJ-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569496P | 2011-12-12 | 2011-12-12 | |
| PCT/US2012/069072 WO2013090319A2 (en) | 2011-12-12 | 2012-12-12 | Treatment of type i and type ii diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014289A8 BR112014014289A8 (pt) | 2017-06-13 |
| BR112014014289A2 true BR112014014289A2 (pt) | 2017-06-13 |
Family
ID=48613352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014289A BR112014014289A2 (pt) | 2011-12-12 | 2012-12-12 | método de tratamento de diabetes, formulação para administração oral, composição, e, uso de qualquer um ou mais dos compostos fenoxipirimidinona e insulina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150190396A1 (enExample) |
| EP (1) | EP2790704B1 (enExample) |
| JP (1) | JP6152387B2 (enExample) |
| KR (1) | KR102069395B1 (enExample) |
| CN (2) | CN107007608B (enExample) |
| AU (2) | AU2012352480A1 (enExample) |
| BR (1) | BR112014014289A2 (enExample) |
| CA (1) | CA2859156C (enExample) |
| IL (1) | IL233004B (enExample) |
| MX (1) | MX359171B (enExample) |
| RU (1) | RU2646475C2 (enExample) |
| SG (2) | SG10201604828QA (enExample) |
| WO (1) | WO2013090319A2 (enExample) |
| ZA (1) | ZA201404738B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10863264B2 (en) | 2017-01-23 | 2020-12-08 | David Sampson | Vibration inducing tactile apparatus |
| MX2020007006A (es) * | 2018-01-11 | 2022-10-03 | Bukwang Pharmaceutical Co Ltd | Metodo para preparar tolimidona en gran escala. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922345A (en) | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20070025953A1 (en) * | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| KR101577554B1 (ko) * | 2005-08-22 | 2015-12-14 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제 |
| RU2316339C1 (ru) * | 2006-09-13 | 2008-02-10 | Общество С Ограниченной Ответственностью "Концерн О3" | Способ получения препарата инсулина для перорального применения |
| AU2008218765A1 (en) * | 2007-02-20 | 2008-08-28 | Melior Pharmaceuticals I, Inc. | Methods of identifying activators of lyn kinase |
| EP2180894A4 (en) | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | METHOD OF ACTIVATING IRS-1 AND ACT |
| DK2355829T3 (en) * | 2008-12-12 | 2015-02-16 | Poxel S A S | COMBINATION OF INSULIN WITH tetrazine AND ITS USE FOR THE TREATMENT OF DIABETES |
| WO2011150300A1 (en) * | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3609500B1 (en) * | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
-
2012
- 2012-12-12 MX MX2014006990A patent/MX359171B/es active IP Right Grant
- 2012-12-12 SG SG10201604828QA patent/SG10201604828QA/en unknown
- 2012-12-12 BR BR112014014289A patent/BR112014014289A2/pt not_active Application Discontinuation
- 2012-12-12 CN CN201610988112.1A patent/CN107007608B/zh active Active
- 2012-12-12 JP JP2014547360A patent/JP6152387B2/ja active Active
- 2012-12-12 KR KR1020147019062A patent/KR102069395B1/ko active Active
- 2012-12-12 RU RU2014128528A patent/RU2646475C2/ru active
- 2012-12-12 EP EP12857229.4A patent/EP2790704B1/en active Active
- 2012-12-12 AU AU2012352480A patent/AU2012352480A1/en not_active Abandoned
- 2012-12-12 WO PCT/US2012/069072 patent/WO2013090319A2/en not_active Ceased
- 2012-12-12 CN CN201280069531.5A patent/CN104271140B/zh active Active
- 2012-12-12 US US14/364,792 patent/US20150190396A1/en not_active Abandoned
- 2012-12-12 SG SG11201403207WA patent/SG11201403207WA/en unknown
- 2012-12-12 CA CA2859156A patent/CA2859156C/en active Active
-
2014
- 2014-06-08 IL IL233004A patent/IL233004B/en unknown
- 2014-06-26 ZA ZA2014/04738A patent/ZA201404738B/en unknown
-
2017
- 2017-07-07 AU AU2017204652A patent/AU2017204652B2/en active Active
-
2020
- 2020-01-08 US US16/737,200 patent/US20200215068A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2790704A2 (en) | 2014-10-22 |
| CN104271140A (zh) | 2015-01-07 |
| IL233004B (en) | 2020-01-30 |
| JP2015513310A (ja) | 2015-05-07 |
| EP2790704B1 (en) | 2019-04-03 |
| US20150190396A1 (en) | 2015-07-09 |
| US20200215068A1 (en) | 2020-07-09 |
| KR20140107416A (ko) | 2014-09-04 |
| CN107007608A (zh) | 2017-08-04 |
| SG11201403207WA (en) | 2014-09-26 |
| BR112014014289A8 (pt) | 2017-06-13 |
| JP6152387B2 (ja) | 2017-06-21 |
| WO2013090319A3 (en) | 2014-12-04 |
| NZ626495A (en) | 2016-03-31 |
| HK1202819A1 (en) | 2015-10-09 |
| AU2017204652A1 (en) | 2017-07-27 |
| AU2017204652B2 (en) | 2018-08-16 |
| SG10201604828QA (en) | 2016-07-28 |
| KR102069395B1 (ko) | 2020-01-22 |
| CA2859156C (en) | 2020-10-06 |
| MX2014006990A (es) | 2015-02-05 |
| RU2646475C2 (ru) | 2018-03-05 |
| CN107007608B (zh) | 2021-04-23 |
| IL233004A0 (en) | 2014-07-31 |
| EP2790704A4 (en) | 2015-09-02 |
| ZA201404738B (en) | 2016-10-26 |
| MX359171B (es) | 2018-09-18 |
| RU2014128528A (ru) | 2016-02-10 |
| AU2012352480A1 (en) | 2014-07-17 |
| CA2859156A1 (en) | 2013-06-20 |
| CN104271140B (zh) | 2016-11-23 |
| WO2013090319A2 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| HUE043540T2 (hu) | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben | |
| BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
| BR112015006019A2 (pt) | composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção. | |
| BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
| BR112014021103A8 (pt) | anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
| BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112013029208A2 (pt) | método para preparar um ou mais oligossarídeos de leite humano ou derivados ou precursores dos mesmos, uso de oligossacarídeos, e, composto | |
| BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| CL2014001437A1 (es) | Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades. | |
| BR112013001571A2 (pt) | composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40 | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |